The Aurum Institute: Tembisa Clinical Research Centre, Clinic 4
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mngadi, Kathryn
Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting
3b
500000
RoW
Booster vaccine
Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine
SARS CoV 2 Infection
01/22
06/23
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
BREACH-TB, NCT06568484: Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

Not yet recruiting
3
2530
RoW
Bedaquiline, Sirturo, Isoniazid, rifapentine, 3HP, 1HP, Levofloxacin, Levaquin
Johns Hopkins University, Elizabeth Glaser Pediatric AIDS Foundation, United States Agency for International Development (USAID)
Tuberculosis, Latent
11/27
11/27
AUR1-8-341, NCT05515042: Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Active, not recruiting
2
694
RoW
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
The Aurum Institute NPC, Coalition for Epidemic Preparedness Innovations
COVID-19
06/24
12/24
NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
1/2
1256
Europe, Canada, US, RoW
Flu mRNA, GSK4382276A, Control 1, Control 2
GlaxoSmithKline, CureVac
Influenza, Human
07/24
08/24
MATRIX-003, NCT06163274: Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings

Recruiting
1
100
US, RoW
Placebo Intravaginal Ring A, Placebo Intravaginal Ring B
University of Pittsburgh, United States Agency for International Development (USAID), Oak Crest Institute of Science
Safety, Acceptability
02/25
12/25
Henning, Anja
AUR1-8-341, NCT05515042: Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Active, not recruiting
2
694
RoW
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
The Aurum Institute NPC, Coalition for Epidemic Preparedness Innovations
COVID-19
06/24
12/24
Nair, Shanal
AUR1-8-341, NCT05515042: Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Active, not recruiting
2
694
RoW
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
The Aurum Institute NPC, Coalition for Epidemic Preparedness Innovations
COVID-19
06/24
12/24

Download Options